Gilteritinib

Key Product Details

Product Description

Gilteritinib is a potent Fms-like tyrosine kinase 3 (FLT3) and AXL inhibitor (IC₅₀ = 0.29 nM and 0.73 nM, for FLT3 and AXL, respectively). In vivo, Gilteritinib reduces tumor growth and improves survival in xenograft and intra-bone marrow transplantation models of FLT3 mutated acute myeloid leukemia. Gilteritinib is orally bioavailable.

Product Specifications for Gilteritinib

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Gilteritinib

The following data is based on the product molecular weight 552.71.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	18.09 mL	90.46 mL	180.93 mL
0.5 mM	3.62 mL	18.09 mL	36.19 mL
1 mM	1.81 mL	9.05 mL	18.09 mL
5 mM	0.36 mL	1.81 mL	3.62 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Mori Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest.New Drugs 2017 PMID: 28516360

Product Documents for Gilteritinib